BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients. The EU-SolidAct trial - European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial - is part of EU-RESPONSE, a pan-European research project involved with the rapid and coordinated investigation of